| Autor: |
Mendelsohn, Simon C, Andrade, Bruno B, Mbandi, Stanley Kimbung, Andrade, Alice M S, Muwanga, Vanessa M, Figueiredo, Marina C, Erasmus, Mzwandile, Rolla, Valeria C, Thami, Prisca K, Cordeiro-Santos, Marcelo, Penn-Nicholson, Adam, Kritski, Afranio L, Hatherill, Mark, Sterling, Timothy R, Scriba, Thomas J, Consortia, the RePORT–South Africa and RePORT–Brazil |
| Zdroj: |
Journal of Infectious Diseases; 12/15/2024, Vol. 230 Issue 6, pe1355-e1365, 11p |
| Abstrakt: |
Background Approximately 5% of people infected with Mycobacterium tuberculosis progress to tuberculosis (TB) disease without preventive therapy. There is a need for a prognostic test to identify those at highest risk of incident TB so that therapy can be targeted. We evaluated host blood transcriptomic signatures for progression to TB disease. Methods Close contacts (≥4 hours of exposure per week) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil. Investigation for incident, microbiologically confirmed, or clinically diagnosed pulmonary or extrapulmonary TB disease through 24 months of follow-up was symptom triggered. Twenty previously validated blood TB transcriptomic signatures were measured at baseline by real-time quantitative polymerase chain reaction. Prognostic performance for incident TB was tested by receiver operating characteristic curve analysis at 6, 9, 12, and 24 months of follow-up. Results Between June 2015 and June 2019, 1854 close contacts were enrolled. Twenty-five progressed to incident TB, of whom 13 had microbiologically confirmed disease. Baseline transcriptomic signature scores were measured in 1789 close contacts. Prognostic performance for all signatures was best within 6 months of diagnosis. Seven signatures (Gliddon4, Suliman4, Roe3, Roe1, Penn-Nicholson6, Francisco2, and Rajan5) met the minimum World Health Organization target product profile for a prognostic test through 6 months and 3 signatures (Gliddon4, Rajan5, and Duffy9) through 9 months. None met the target product profile threshold through ≥12 months of follow-up. Conclusions Blood transcriptomic signatures may be useful for predicting TB risk within 9 months of measurement among TB-exposed contacts to target preventive therapy administration. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
